June 8, 2020 / 12:12 PM / a month ago

BRIEF-Insmed Receives FDA Breakthrough Therapy Designation For Brensocatib In Patients With Non-Cystic Fibrosis Bronchiectasis

June 8 (Reuters) - Insmed Inc:

* INSMED RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR BRENSOCATIB IN PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS (NCFBE)

* INSMED INC - EXPECTS TO INITIATE A PHASE 3 PROGRAM FOR BRENSOCATIB IN BRONCHIECTASIS IN SECOND HALF OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below